Live feed08:00:00·980dPRReleasevia QuantisnowNKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid TumorsByQuantisnow·Wall Street's wire, on your screen.GFOR· Graf Acquisition Corp. IVFinance
